| Coral Bay Healthcare And Rehabilitation | |
| 2939 S Haverhill Rd, West Palm Beach, Florida 33415 | |
| (561) 641-3130 | |
| Name | Coral Bay Healthcare And Rehabilitation |
|---|---|
| Location | 2939 S Haverhill Rd, West Palm Beach, Florida |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 90.83% |
| Medicare ID (CCN) | 105795 |
| Legal Business Name | 2939 South Haverhill Road Operations Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1265204572 |
| Organization Name | 2939 S HAVERHILL RD OPCO LLC |
| Doing Business As | ASPIRE AT CORAL BAY |
| Address | 2939 S Haverhill Rd, West Palm Beach, FL 33415 |
| Phone Number | 561-641-3130 |
News Archive
Dental caries is a highly prevalent disease that is disproportionately distributed in the population. Caries occurrence and progression is known to be influenced by a complex interplay of both environmental and genetic factors, with numerous contributing factors having been identified including bacterial flora, dietary habits, fluoride exposure, oral hygiene, salivary flow, salivary composition, and tooth structure. Previous reports have characterized the influence of the genetic variation on taste preferences and dietary habits.
Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-Release Tablets, 40mg.
GenVec, Inc, announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
A team led by scientists at The Scripps Research Institute has determined the basic structural organization of a molecular motor that hauls cargoes and performs other critical functions within cells.
Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).
› Verified 6 days ago
| NPI Number | 1588933360 |
| Organization Name | 2939 SOUTH HAVERHILL ROAD OPERATIONS LLC |
| Doing Business As | CORAL BAY HEALTHCARE AND REHABILITATION |
| Address | 2939 S Haverhill Rd, West Palm Beach, FL 33415 |
| Phone Number | 561-641-3130 |
News Archive
Dental caries is a highly prevalent disease that is disproportionately distributed in the population. Caries occurrence and progression is known to be influenced by a complex interplay of both environmental and genetic factors, with numerous contributing factors having been identified including bacterial flora, dietary habits, fluoride exposure, oral hygiene, salivary flow, salivary composition, and tooth structure. Previous reports have characterized the influence of the genetic variation on taste preferences and dietary habits.
Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-Release Tablets, 40mg.
GenVec, Inc, announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
A team led by scientists at The Scripps Research Institute has determined the basic structural organization of a molecular motor that hauls cargoes and performs other critical functions within cells.
Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).
› Verified 6 days ago
| NPI Number | 1952356313 |
| Organization Name | CORAL BAY HEALTH CARE ASSOCIATES LLC |
| Doing Business As | CORAL BAY HEALTHCARE AND REHABILITATION |
| Address | 2939 S Haverhill Rd, West Palm Beach, FL 33415 |
| Phone Number | 561-641-3130 |
News Archive
Dental caries is a highly prevalent disease that is disproportionately distributed in the population. Caries occurrence and progression is known to be influenced by a complex interplay of both environmental and genetic factors, with numerous contributing factors having been identified including bacterial flora, dietary habits, fluoride exposure, oral hygiene, salivary flow, salivary composition, and tooth structure. Previous reports have characterized the influence of the genetic variation on taste preferences and dietary habits.
Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-Release Tablets, 40mg.
GenVec, Inc, announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
A team led by scientists at The Scripps Research Institute has determined the basic structural organization of a molecular motor that hauls cargoes and performs other critical functions within cells.
Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Dental caries is a highly prevalent disease that is disproportionately distributed in the population. Caries occurrence and progression is known to be influenced by a complex interplay of both environmental and genetic factors, with numerous contributing factors having been identified including bacterial flora, dietary habits, fluoride exposure, oral hygiene, salivary flow, salivary composition, and tooth structure. Previous reports have characterized the influence of the genetic variation on taste preferences and dietary habits.
Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-Release Tablets, 40mg.
GenVec, Inc, announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
A team led by scientists at The Scripps Research Institute has determined the basic structural organization of a molecular motor that hauls cargoes and performs other critical functions within cells.
Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 14.24 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4.11 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 44.17 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.45 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.57 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.58 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 7.58 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.27 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 27.33 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 14.49 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.56 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 66.3 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 96.61 | 82.93 |
News Archive
Dental caries is a highly prevalent disease that is disproportionately distributed in the population. Caries occurrence and progression is known to be influenced by a complex interplay of both environmental and genetic factors, with numerous contributing factors having been identified including bacterial flora, dietary habits, fluoride exposure, oral hygiene, salivary flow, salivary composition, and tooth structure. Previous reports have characterized the influence of the genetic variation on taste preferences and dietary habits.
Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-Release Tablets, 40mg.
GenVec, Inc, announced today that SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
A team led by scientists at The Scripps Research Institute has determined the basic structural organization of a molecular motor that hauls cargoes and performs other critical functions within cells.
Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).
› Verified 6 days ago
Rehabilitation Center Of The Palm Beaches,the Location: 301 Northpointe Parkway, West Palm Beach, Florida 33407 Phone: (561) 712-1717 | |
Lakeside Health Center Location: 2501 N Australian Avenue, West Palm Beach, Florida 33407 Phone: (561) 655-7780 | |
Lourdes-noreen Mckeen Residence For Geriatric Care Location: 315 S Flagler Dr, West Palm Beach, Florida 33401 Phone: (561) 655-8544 | |
Consulate Health Care Of West Palm Beach Location: 1626 Davis Rd, West Palm Beach, Florida 33406 Phone: (561) 439-8897 | |
Darcy Hall Of Life Care Location: 2170 Palm Beach Lakes Blvd, West Palm Beach, Florida 33409 Phone: (561) 683-3333 | |
Renaissance Health And Rehabilitation Location: 5065 Wallis Road, West Palm Beach, Florida 33415 Phone: (561) 689-1799 |